SCHEMBL6490491

SCHEMBL6490491

CCC(=O)Nc1c(C)cc(OCc2ccccc2C(=O)OC)cc1[N+](=O)[O-]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 4/20 0.45
KMT2A Q03164 3/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
LMNA P02545 1/20 0.44
MEN1 O00255 2/20 0.43
KDM4E B2RXH2 2/20 0.43
MAOB P27338 1/20 0.40
PDGFRB P09619 1/20 0.40
FGFR1 P11362 1/20 0.40
PDGFRA P16234 1/20 0.40
FLT1 P17948 1/20 0.40
FGFR3 P22607 1/20 0.40
KDR P35968 1/20 0.40
OPRL1 P41146 1/20 0.39
MAPT P10636 4/20 0.39
GAA P10253 1/20 0.39
HTT P42858 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6502928 0.90 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1KMT2AL3MBTL1LMNA
SCHEMBL6488469 0.87 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1KMT2AL3MBTL1MEN1
SCHEMBL6487920 0.83 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1KMT2AL3MBTL1LMNA
SCHEMBL7131566 0.80 KMT2A (0.44) SMN1; SMN2ALDH1A1KMT2AL3MBTL1LMNA
SCHEMBL6499184 0.76 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1KMT2AMEN1KDM4E
SCHEMBL6489011 0.76 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1KMT2AL3MBTL1MEN1
SCHEMBL8268147 0.75 LMNA (0.45) SMN1; SMN2ALDH1A1KMT2AL3MBTL1LMNA
SCHEMBL6829590 0.74 L3MBTL1 (0.45) SMN1; SMN2ALDH1A1KMT2AL3MBTL1LMNA
SCHEMBL6829591 0.74 L3MBTL1 (0.45) SMN1; SMN2ALDH1A1KMT2AL3MBTL1LMNA
SCHEMBL8128216 0.74 KMT2A (0.56) SMN1; SMN2ALDH1A1KMT2AL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD SMN1; SMN2 1128/4885ALDH1A1 96/4885KMT2A 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.